Many Marylanders struggle with obesity but cannot get access to weight loss medications because insurance will not pay for ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

Commercial insurance coverage of blockbuster GLP-1 drugs has not expanded much over the past year, despite growing demand and expanded indications, according to a new report from GoodRx. Data from ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

A holistic approach emphasizes lifestyle choices, nutrition, exercise, stress management, medications where appropriate, and ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

As weight loss drugs continue to grow in popularity in the U.S., some health leaders are warning about fake drugs on the ...